| Line Item | 2025-09-30 | Q/Q | Y/Y |
|---|---|---|---|
| R&D Expense | $4.0M | +21.5% | +30.3% |
| SG&A Expense | $3.6M | +23.1% | +69.0% |
| Operating Income | -$7.6M | -22.2% | -46.0% |
| Net Income | -$7.5M | -21.7% | -48.0% |
| EPS (Basic) | -$2.23 | +73.5% | -364.6% |
| EPS (Diluted) | -$2.23 | +73.5% | -364.6% |
| Line Item | 2025-09-30 | Q/Q | Y/Y |
|---|---|---|---|
| Cash & Equivalents | $21.1M | +123.8% | +171.6% |
| Current Assets | $22.6M | +104.4% | +126.2% |
| Total Assets | $27.0M | +72.8% | +78.2% |
| Current Liabilities | $5.6M | +14.8% | -4.6% |
| Total Liabilities | $9.6M | +5.5% | -10.5% |
| Stockholders' Equity |
| Line Item | 2025-09-30 | Q/Q | Y/Y |
|---|---|---|---|
| Operating Cash Flow | -$20.4M | — | — |
| Financing Cash Flow | $32.7M | — | — |
| $17.4M |
| +166.6% |
| +293.5% |